A mechanistic approach for the scaling of clearance in children

Clinical Pharmacokinetics

Volumn 45, Issue 7, 2006, Pages 683-704

  Edginton, Andrea N ^a   Schmitt, Walter ^a   Voith, Barbara ^b   Willmann, Stefan ^a  

^a BAYER AG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; ANTIBIOTIC AGENT; BUPRENORPHINE; CAFFEINE; CIPROFLOXACIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FENTANYL; GENTAMICIN; GLUCURONOSYLTRANSFERASE; ISEPAMICIN; LIDOCAINE; LIVER ENZYME; LOCAL ANESTHETIC AGENT; LORAZEPAM; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; PARACETAMOL; ROPIVACAINE; THEOPHYLLINE;

ADOLESCENT; ADULT; ARTICLE; BILIARY EXCRETION; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG RESEARCH; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; LIVER METABOLISM; NEWBORN; ONTOGENY; PLASMA CLEARANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SULFONATION;

AGING; BILE; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; GLOMERULAR FILTRATION RATE; GLUCURONIDES; HUMANS; KIDNEY; LIVER; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SULFONIC ACIDS;

EID: 33745599327     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645070-00004     Document Type: Article

References (185)

1. Choonara I. Unlicensed and off-label drug use in children: implications for safety. Expert Opin Drug Saf 2004; 3 (2): 81-3
2. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Saf 2002; 25 (1): 1-5
3. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320 (7227): 79-82
4. Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88 (9): 965-8
5. Schirm E, Tobi H, de Jong-van den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003; 111 (2): 291-5
6. McNamara PJ, Alcorn J. Protein binding predictions in infants. AAPS PharmSci 2002; 4 (1): 1-8
7. International Commission on Radiological Protection (ICRP). Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89. Amsterdam: Elsevier Science, 2002
8. Lopez Barrio AM, De Palma Gaston MA, Munoz Conde J. Evaluation of the portal blood flow in healthy children by doppler duplex echography [in Spanish]. An Esp Pediatr 1996; 44 (1): 45-9
9. Kagimoto S, Fujisuka S, Kinoshita K, et al. Study to establish normal values for portal vein blood flow in children using a duplex ultrasound system. Acta Paediatr Jpn 1991; 33 (6): 693-6
10. Winso O, Biber B, Gustavsson B, et al. Portal blood flow in man during graded positive end-expiratory pressure ventilation. Intensive Care Med 1985; 12 (2): 80-8
11. Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev 1971; 51 (1): 23-5
12. Bjorkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 2004; 59 (6): 691-704
13. Darrow DC, Cary MK. The serum albumin and globulin of newborn, premature and normal infants. J Pediatr 1933; 3: 573-9
14. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32 (3): 210-58
15. Hardman JG, Limbird LE, editors. Goodman and Gilman's: the pharmacological basis of therapeutics. 10th ed. New York: McGraw Hill, 2001
16. Lin C, Korduba C, Affrime M, et al. Pharmacokinetics and metabolism of 14C-isepamicin in humans following intravenous administration. Antimicrob Agents Chemother 1995; 39 (10): 2201-3
17. Halstenson CE, Kelloway JS, Affrime MB, et al. Isepamicin disposition in subjects with various degrees of renal function. Antimicrob Agents Chemother 1991; 35 (11): 2382-7
18. Chauvin M, Bonnet F, Montembault C, et al. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986; 65 (10): 999-1003
19. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997; 87 (1): 36-50
20. Roure P, Jean N, Leclerc AC, et al. Pharmacokinetics of alfentanil in children undergoing surgery. Br J Anaesth 1987; 59 (11): 1437-40
21. Macfie AG, Magides AD, Reilly CS. Disposition of alfentanil in burns patients. Br J Anaesth 1992; 69 (5): 447-50
22. Smith MT, Eadie MJ, Brophy O. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981; 19 (4): 271-8
23. Sen S, Ytrebo LM, Rose C, et al. Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. Intensive Care Med 2004; 30 (3): 496-501
24. Dorne JL, Walton K, Renwick AG. Uncertainty factors for chemical risk assessment: human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem Toxicol 2001; 39 (7): 681-96
25. Blanchard J, Sawers SJ. Comparative pharmacokinetics of caffeine in young and elderly men. J Pharmacokinet Biopharm 1983; 11 (2): 109-26
26. Valko K, Nunhuck S, Bevan C, et al. Fast gradient HPLC method to determine compounds binding to human serum albumin: relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci 2003; 92 (11): 2236-48
27. Arlander E, Ekstrom G, Alm C, et al. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998; 64 (5): 484-91
28. Ekstrom G, Gunnarsson U. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996; 24 (9): 955-9
29. Mazoit JX, Dalens BJ. Pharmacokinetics of local anaesthetics in infants and children. Clin Pharmacokinet 2004; 43 (1): 17-32
30. Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review. Part 1: pharmacokinetics. Paediatr Anaesth 1997; 7 (1): 5-11
31. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106 (1): 97-132
32. de Wildt SN, Kearns GL, Leeder JS, et al. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36 (6): 439-52
33. Crom WR, Relling MV, Christensen ML, et al. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. Clin Pharmacol Ther 1991; 50 (2): 132-40
34. Oda Y, Mizutani K, Hase I, et al. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. Br J Anaesth 1999; 82 (6): 900-3
35. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet 1983; 8 (5): 422-46
36. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 1982; 7 (2): 93-107
37. Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum [alpha]-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit 2004; 26 (1): 40-3
38. Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004; 76 (6): 598-606
39. Davis RL, Koup JR, Williams-Warren J, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987; 31 (6): 915-9
40. Shah A, Lettieri J, Heller A, et al. Pharmacokinetics of IV ciprofloxacin in subjects with normal renal function and with various degrees of renal impairment. Internal Report No. R6098. West Haven (CN). Institute of Clinical Pharmacology International, Bayer HealthCare - Pharma. 1993
41. Sorgel F, Naber KG, Jaehde U, et al. Gastrointestinal secretion of ciprofloxacin: evaluation of the charcoal model for investigations in healthy volunteers. Am J Med 1989; 87 (5A): S62-5
42. Davis RL, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51 (6): 1019-74
43. Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64 (3): 276-82
44. Kobayshi K, Yamamoto T, Chiba K, et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998; 26 (8): 818-21
45. Mihaly GW, Moore G, Thomas J, et al. The pharmacokinetics and metabolism of the anilide local anaesthetics in neonates. Eur J Clin Pharmacol 1978; 13 (2): 143-52
46. Orlando R, Piccoli P, De MS, et al. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004; 75 (1): 80-8
47. Pons G, Blais J, Rey E, et al. Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test. Pediatr Res 1988; 23 (6): 632-6
48. Hansen TG, Ilett KF, Reid C, et al. Caudal ropivacaine in infants: population pharmacokinetics and plasma concentrations. Anesthesiology 2001; 94 (4): 579-84
49. McCann ME, Sethna NF, Mazoit JX, et al. The pharmacokinetics of epidural ropivacaine in infants and young children. Anesth Analg 2001; 93 (4): 893-7
50. Lonnqvist PA, Westrin P, Larsson BA, et al. Ropivacaine pharmacokinetics after caudal block in 1-8 year old children. Br J Anaesth 2000; 85 (4): 506-11
51. Van Obbergh LJ, Roelants FA, Veyckemans F, et al. In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. Can J Anaesth 2003; 50 (6): 593-8
52. Habre W, Bergesio R, Johnson C, et al. Pharmacokinetics of ropivacaine following caudal analgesia in children. Paediatr Anaesth 2000; 10 (2): 143-7
53. Ecoffey C, Desparmet J, Berdeaux A, et al. Pharmacokinetics of lignocaine in children following caudal anaethesia. Br J Anaesth 1984; 56 (12): 1399-402
54. Hook JB, Baillie MD. Perinatal renal pharmacology. Annu Rev Pharmacol Toxicol 1979; 19: 491-509
55. Rubin M, Bruck E, Rapoport M. Maturation of renal function in childhood: clearance studies. J Clin Invest 1949; 28: 1144-62
56. Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs. AAPS PharmSci 2002; 2 (1): 1-7
57. Leake RD, Trygstad CW, Oh W. Inulin clearance in the newborn infant: relationship to gestational and postnatal age. Pediatr Res 1976; 10 (8): 759-62
58. Leake RD, Trygstad CW. Glomerular filtration rate during the period of adaptation to extrauterine life. Pediatr Res 1977; 92 (5): 705-12
59. Sato Y. Pharmacokinetics of antibiotics in neonates. Acta Paediatr Jpn 1997; 39 (1): 124-31
60. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and induciblity in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199 (3): 193-209
61. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004; 76 (6): 618-27
62. de Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999; 37 (6): 485-505
63. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300 (2): 355-60
64. Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 1997; 61 (26): 2567-74
65. Treluyer JM, Bowers G, Cazali N, et al. Oxidative metabolism of amprenavir in the human liver: effect of the CYP3A maturation. Drug Metab Dispos 2003; 31 (3): 275-81
66. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 2002; 41 (12): 959-98
67. Blanco JG, Harrison PL, Evans WE, et al. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos 2000; 28 (4): 379-82
68. Dorne JL, Walton K, Renwick AG. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem Toxicol 2003; 41 (2): 201-24
69. Sonnier M, Cresteil T. Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 1998; 251 (3): 893-8
70. Johnsrud EK, Koukouritaki SB, Divakaran K, et al. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003; 307 (1): 402-7
71. Rollins DE, von Bahr C, Glaumann H, et al. Acetaminophen: potentially toxic metabolite formed by human fetal and adult liver microsomes and isolated fetal liver cells. Science 1979; 205 (4413): 1414-6
72. Vieira I, Sonnier M, Cresteil T. Developmental expression of CYP2E1 in the human liver: hypermethylation control of gene expression during the neonatal period. Eur J Biochem 1996; 238 (2): 476-83
73. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300 (2): 361-3
74. Pacifici GM, Sawe J, Kager L, et al. Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol 1982; 22 (6): 553-8
75. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50 (2): 259-65
76. Alam SN, Roberts RJ, Fischer LJ. Age-related differences in salicylamide and acetaminophen conjugation in man. J Pediatr 1977; 90 (1): 130-5
77. Pacifici GM, Kubrich M, Giuliani L, et al. Sulphation and glucuronidation of ritodrine in human foetal and adult tissues. Eur J Clin Pharmacol 1993; 44 (3): 259-64
78. Levy G, Khanna NN, Soda DM, et al. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. Pediatrics 1975; 55 (6): 818-25
79. Brashear WT, Kuhnert BR, Wei R. Maternal and neonatal urinary excretion of sulfate and glucuronide ritodrine conjugates. Clin Pharmacol Ther 1988; 44 (6): 634-41
80. Van Lingen RA, Deinum JT, Quak JM, et al. Pharmacokinetics and metabolism of rectally administered paracetamol in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80 (1): F59-63
81. Van der Marel CD, Anderson BJ, Van Lingen RA, et al. Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin Pharmacol 2003; 59 (3): 243-51
82. Miller RP, Roberts RJ, Fischer LJ. Acetaminophen elimination kinetics in neonates, children, and adults. Clin Pharmacol Ther 1976; 19 (3): 284-94
83. Kauffman FC. Sulfonation in pharmacology and toxicology. Drug Metab Rev 2004; 36 (3-4): 823-43
84. Richard K, Hume R, Kaptein E, et al. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab 2001; 86 (6): 2734-42
85. Dorne JL, Walton K, Renwick AG. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). Food Chem Toxicol 2004; 42 (3): 397-421
86. Cagen SZ, Gibson JE. Characteristics of hepatic excretory function during development. J Pharmacol Exp Ther 1979; 210 (1): 15-21
87. Balistreri WF. Immaturity of hepatic excretory function and the ontogeny of bile acid metabolism. J Pediatr Gastroenterol Nutr 1983; 2 (S1): S207-14
88. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284 (5420): 1677-9
89. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9 (4): 503-12
90. Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47: 637-43
91. Vervelde ML, Rademaker CM, Krediet TG, et al. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit 1999; 21 (5): 514-9
92. Assael BM, Cavanna G, Jusko WJ, et al. Multiexponential elimination of gentamicin: a kinetic study during development. Dev Pharmacol Ther 1980; 1 (2-3): 171-81
93. Pons G, d'Athis P, Rey E, et al. Gentamicin monitoring in neonates. Ther Drug Monit 1988; 10 (4): 421-7
94. Rocha MJ, Almeida AM, Afonso E, et al. The kinetic profile of gentamicin in premature neonates. J Pharm Pharmacol 2000; 52 (9): 1091-7
95. Ho KK, Bryson SM, Thiessen JJ, et al. The effects of age and chemotherapy on gentamicin pharmacokinetics and dosing in pediatric oncology patients. Pharmacotherapy 1995; 15 (6): 754-64
96. Gonzalez-Martin G, Bravo I, Vargas H, et al. Pharmacokinetics of gentamicin in children with nephrotic syndrome. Int J Clin Pharmacol Ther Toxicol 1986; 24 (10): 555
97. Scaglione F, Vigano A, Colucci R, et al. Pharmacokinetics of isepamicin in paediatric patients. J Chemother 1995; 7 (S2): 63-9
98. Nomeir AA, Radwanski E, Cutler D, et al. Single-dose pharmacokinetics of isepamicin in young and geriatric volunteers. J Clin Pharmacol 1997; 37 (11): 1021-30
99. Radwanski E, Batra V, Cayen M, et al. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. Antimicrob Agents Chemother 1997; 41 (8): 1794-6
100. Davis PJ, Killian A, Stiller RL, et al. Pharmacokinetics of alfentanil in newborn premature infants and older children. Dev Pharmacol Ther 1989; 13 (1): 21-7
101. Marlow N, Weindling AM, Van Peer A, et al. Alfentanil pharmacokinetics in preterm infants. Arch Dis Child 1990; 65 (4): 349-51
102. Kharasch ED, Russell M, Garton K, et al. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997; 87 (1): 26-35
103. Killian A, Davis PJ, Stiller RL, et al. Influence of gestational age on pharmacokinetics of alfentanil in neonates. Dev Pharmacol Ther 1990; 15 (2): 82-5
104. Wiest DB, Ohning BL, Garner SS. The disposition of alfentanil in neonates with respiratory distress. Pharmacotherapy 1991; 11 (4): 308-11
105. Goresky GV, Koren G, Sabourin MA, et al. The pharmacokinetics of alfentanil in children. Anesthesiology 1987; 67 (5): 654-9
106. den Hollander JM, Hennis PJ, Burm AG, et al. Alfentanil in infants and children with congenital heart defects. J Cardiothorac Anesth 1998; 2 (1): 12-7
107. Meistelman C, Saint-Maurice C, Lepaul M, et al. A comparison of alfentanil pharmacokinetics in children and adults. Anesthesiology 1987; 66 (1): 13-6
108. de Wildt SN, Kearns GL, Hop CJ, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther 2001; 70 (6): 525-31
109. Jacqz-Aigrain E, Wood C, Robieux I. Pharmacokinetics of midazolam in critically ill neonates. Eur J Clin Pharmacol 1990; 39 (3): 191-2
110. Yu KS, Cho JY, Jang IJ, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004; 76 (2): 104-12
111. Mulla H, McCormack P, Lawson G, et al. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 2003; 99 (2): 275-82
112. Reed MD, Rodarte A, Blumer JL, et al. The single-dose pharmacokinetics of midazolam and its primary metabolites in pediatric patients after oral and intravenous administration. J Clin Pharmacol 2001; 41 (12): 1359-69
113. Mathews HM, Carson IW, Lyons SM, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth 1988; 61 (3): 302-7
114. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. Eur J Pharmacol 1989; 37 (3): 267-72
115. Jokinen MJ, Olkkola KT, Ahonen J, et al. Effect of ciprofloxacin on the pharmacokinetics of ropivacaine. Eur J Clin Pharmacol 2003; 58 (10): 653-7
116. Emanuelsson BM, Persson J, Alm C, et al. Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers. Anesthesiology 1997; 87 (6): 1309-17
117. Jokinen MJ, Olkkola KT, Ahonen J, et al. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 2001; 70 (4): 344-50
118. Pere P, Salonen M, Jokinen M, et al. Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block. Anesth Analg 2003; 96 (2): 563-9
119. Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979; 94 (4): 663-8
120. Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978; 24 (1): 40-5
121. Gorodischer R, Karplus M. Pharmacokinetic aspects of caffeine in premature infants with apnoea. Eur J Clin Pharmacol 1982; 22 (1): 47-52
122. Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther 1997; 61 (6): 628-40
123. Lee HS, Khoo YM, Chirino-Barcelo Y, et al. Caffeine in apnoeic Asian neonates: a sparse data analysis. Br J Clin Pharmacol 2002; 54 (1): 31-7
124. Pons G, Carrier O, Richard MO, et al. Developmental changes in caffeine elimination in infancy. Dev Pharmacol Ther 1988; 11 (5): 258-64
125. Baillie SP, Bateman DN, Coates PE, et al. Age and the pharmacokinetics of morphine. Age Aging 1989; 18 (4): 258-62
126. Skarke C, Schmidt H, Geisslinger G, et al. Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. Br J Clin Pharmacol 2003; 56 (2): 228-31
127. Mikkelsen S, Feilberg VL, Chistensen CB, et al. Morphine pharmacokinetics in premature and mature newborn infants. Acta Paediatr 1994; 83 (10): 1025-8
128. Saarenmaa E, Neuvonen PJ, Rosenberg P, et al. Morphine clearance and effects in newborn infants in relation to gestational age. Clin Pharmacol Ther 2000; 68 (2): 160-6
129. Lynn AM, Nespeca MK, Bratton SL, et al. Intravenous morphine in postoperative infants: intermittent bolus dosing versus targeted continuous infusions. Pain 2000; 88 (1): 89-95
130. Lynn A, Nespeca M, Bratton SL, et al. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 1998; 86 (5): 958-63
131. Hain RD, Hardcastle A, Pinkerton CR, et al. Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. Br J Clin Pharmacol 1999; 48 (1): 37-42
132. McDermott CA, Kowalczyk AL, Schnitzler E, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr 1992; 120 (3): 479-83
133. Crom WR, Webster SL, Bobo L, et al. Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 1987; 41 (6): 645-50
134. Relling MV, Mulhern RK, Dodge RK, et al. Lorazepam pharmacodynamics and pharmacokinetics in children. J Pediatr 1989; 114 (4 Pt 1): 641-6
135. Murry DJ, Crom WR, Reddick WE, et al. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab Dispos 1995; 23 (10): 1110-6
136. Kearns GL, Crom WR, Karlson KH, et al. Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmacol Ther 1996; 59 (5): 529-40
137. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75 (2): 223-9
138. Saarenmaa E, Neuvonen PJ, Fellman V. Gestational age and birth weight effects on plasma clearance of fentanyl in newborn infants. J Pediatr 2000; 136 (6): 767-70
139. Ibrahim AE, Feldman J, Karim A, et al. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003; 98 (4): 853-61
140. Koehntop DE, Rodman JH, Brundage DM, et al. Pharmacokinetics of fentanyl in neonates. Anesth Analg 1986; 65 (3): 227-32
141. Gauntlett IS, Fisher DM, Hertzka RE, et al. Pharmacokinetics of fentanyl in neonatal humans and lambs: effects of age. Anesthesiology 1988; 69 (5): 683-7
142. Katz R, Kelly HW. Pharmacokinetics of continuous infusions of fentanyl in critically ill children. Crit Care Med 1993; 21 (7): 995-1000
143. Singleton MA, Rosen JI, Fisher DM. Pharmacokinetics of fentanyl for infants and adults [abstract]. Anesthesiology 1984; 61 (7): A440
144. Dsida RM, Wheeler M, Birmingham PK, et al. Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. Anesth Analg 1998; 86 (1): 66-70
145. Ginsberg B, Howell S, Glass PS, et al. Pharmacokinetic model-driven infusion of fentanyl in children. Anesthesiology 1996; 85 (6): 1268-75
146. Mitenko PA, Ogilvie RI. Pharmacokinetics on intravenous theophylline. Clin Pharmacol Ther 1973; 14 (4): 509-13
147. Islam SI, Ali AS, Sheikh AA, et al. Pharmacokinetics of theophylline in preterm neonates during the first month of life. Saudi Med J 2004; 25 (4): 459-65
148. Stringer KA, Mallet J, Clarke M, et al. The effect of three different oral doses of verapamil on the disposition of theophylline. Eur J Clin Pharmacol 1992; 43 (1): 35-8
149. Aranda JV, Turmen T, Sasyniuk BI. Pharmacokinetics of diuretics and methyl xanthines in the neonate. Eur J Pharmacol 1980; 18: 55-63
150. Prince RA, Casabar E, Adair CG, et al. Effect of quinolone antimicrobials on theophylline pharmacokinetics. J Clin Pharmacol 1989; 29 (7): 650-4
151. Simons FE, Simons KJ. Pharmacokinetics of theophylline in infancy. J Clin Pharmacol 1978; 18: 472-6
152. Loughnan PM, Sitar DS, Ogilvie RI, et al. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr 1976; 88: 874-9
153. Vichyanond P, Aranyanark N, Visitsuntorn N, et al. Theophylline pharmacokinetics in Thai children. Asian Pac J Allergy Immunol 1994; 12 (2): 137-43
154. Ginchansky E, Weinberger M. Relationship of theophylline clearance to oral dosage in children with chronic asthma. J Pediatr 1977; 91: 655-60
155. Arnold JD, Hill GN, Sansom LN. A comparison of the pharmacokinetics of theophylline in asthmatic children in the acute episode and in remission. Eur J Pharmacol 1981; 20: 443-7
156. Ellis EF, Koysooko R, Levy G. Pharmacokinetics of theophylline in children with asthma. Pediatrics 1976; 58 (4): 542-7
157. Agbaba D, Pokrajac M, Varagic VM, et al. Dependence of the renal excretion of theophylline on its plasma concentrations and urine flow rate in asthmatic children. J Pharmacol 1990; 42: 827-30
158. Bannwarth B, Netter P, Lapicque F, et al. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol 1992; 34 (1): 79-81
159. Allegaert K, Anderson BJ, Naulaers G, et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur J Clin Pharmacol 2004; 60 (3): 191-7
160. Depre M, van Hecken HA, Verbesselt R, et al. Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use. Fundam Clin Pharmacol 1992; 6 (6): 259-62
161. Allegaert K, Van der Marel CD, Debeer A, et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch Dis Child Fetal Neonatal Ed 2004; 89 (1): F25-8
162. Flouvat B, Leneveu A, Fitoussi S, et al. Bioequivalence study comparing a new paracetamol solution for injection and propacetamol after single intravenous infusion in healthy subjects. Int J Clin Pharmacol Ther 2004; 42 (1): 50-7
163. Autret E, Dutertre JP, Breteau M, et al. Pharmacokinetics of paracetamol in the neonate and infant after administration of propacetamol chlorhydrate. Dev Pharmacol Ther 1993; 20 (3-4): 129-34
164. Granry JC, Rod B, Boccard E, et al. Pharmacokinetics and antipyretic effects of an injectable prodrug of paracetamol (proparacetamol) in children. Paediatr Anaesth 1992; 2: 291-5
165. Payen S, Serreau R, Munck A, et al. Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. Antimicrob Agents Chemother 2003; 47 (10): 3170-8
166. Plaisance KI, Drusano GL, Forrest A, et al. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1987; 31 (6): 956-8
167. Hoffken G, Lode H, Prinzing C, et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother 1985; 27 (3): 375-9
168. Rajagopalan P, Gastonguay MR. Population pharmacokinetics of ciprofloxacin in pediatric patients. Pediatrics 2003; 43: 698-710
169. Rey E, Radvanyi-Bouvet MF, Bodiou C, et al. Intravenous lidocaine in the treatment of convulsions in the neonatal period: monitoring plasma levels. Ther Drug Monit 1990; 12: 316-20
170. Finholt DA, Stirt JA, Difazio CA, et al. Lindocaine pharmacokinetics in children during general anesthesia. Anesth Analg 1986; 65 (3): 279-82
171. Burrows FA, Lerman J, Ledez KM, et al. Pharmacokinetics of lidocaine in children. Can J Anaesth 1991; 38 (2): 196-200
172. Kuhlman JJ, Lalani S, Magluilo J. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 2005; 20 (6): 369-78
173. Barrett DA, Simpson J, Rutter N, et al. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol 1993; 36 (3): 215-9
174. Amani A, Joseph T, Balasaraswathi K. Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. Indian J Physiol Pharmacol 1997; 41 (4): 361-8
175. Olkkola KT, Maunuksela EL, Korpela R. Pharmacokinetics of intravenous buprenorphine in children. Br J Clin Pharmacol 1989; 28 (2): 202-4
176. Ginsberg G, Hattis D, Sonawane B. Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 2004; 198 (2): 164-83
177. Alcorn J, McNamara PJ. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 2002; 41 (13): 1077-1
178. Alcorn J, McNamara PJ. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003; 55 (5): 667-86
179. Ginsberg G, Hattis D, Russ A, et al. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J Toxicol Environ Health A 2004; 67 (4): 297-329
180. Best Pharmaceuticals for Children Act, 2002 Jan 4, (Public Law No. 107-109) [online]. Available from URL: http://www.f-da.gov/opacom/laws/ pharmkids/contents.html [Accessed 2006 Jun 16]
181. Proposal for regulation of the European Parliament and of the council on medicinal products for paediatric use and amending Council Regulation (EEC) No. 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 [online]. Available from URL: http://pharmacos.eudra.org/F2/Paediatrics/docs/ _2004_09/EN. pdf
182. Renwick AG, Dorne JL, Walton K. An analysis of the need for an additional uncertainty factor for infants and children. Regul Toxicol Pharmacol 2000; 31 (3): 286-2
183. Ginsberg G, Hattis D, Miller RM, et al. Pediatric pharmacokinetic data: implications for environmental risk assessment for children. Pediatrics 2004; 113 (4): 973-83
184. Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005; 59 (6): 663-9
185. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiology-based pharmacokinetic (PBPK) model for children. Clin Pharmacokinet 2006. In press.